UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
------------------------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
------------------------
Date of Report (Date of earliest event reported): October 8, 2002
IMMUNOGEN, INC.
(Exact name of registrant as specified in its Charter)
Massachusetts 0-17999 04-2726691
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)
128 Sidney Street, Cambridge, Massachusetts 02139
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (617) 995-2500
ITEM 5. OTHER EVENTS
On October 8, 2002, Boehringer Ingelheim GmbH informed ImmunoGen, Inc. that
clinical trials of the novel anti-cancer agent composed of ImmunoGen's DM1
Tumor-Activated Prodrug (TAP technology) and Boehringer Ingelheim's anti-CD44v6
antibody had been initiated on or about September 24, 2002. The achievement of
this milestone triggers a milestone payment of $1.0 million from Boehringer
Ingelheim to ImmunoGen. This milestone payment will be recognized as revenue in
ImmunoGen's quarter ended September 30, 2002, the period in which the milestone
payment was earned. The press release announcing the achievement of this
milestone is incorporated herein by reference and filed as Exhibit 99.1 hereto.
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS
(c) Exhibits.
99.1 The Registrant's Press Release dated October 15, 2002.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereto duly authorized.
ImmunoGen, Inc.
(Registrant)
Date: October 15, 2002 /s/ GREGG D. BELOFF
-----------------------------------
Gregg D. Beloff
Chief Financial Officer
and Vice President